GLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 - Landscape Led by China and the U.S., Rising Partnerships, and Strong DTC-Driven Demand Push Biologics Above 65% Share

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Approximately 60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development, with most targeting metabolic disorders such as Type 2 diabetes and obesity

  80% confidence

• The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period

  80% confidence

• Close to 50% of partnerships related to GLP-1 drugs were signed for drug development and commercialization

  80% confidence

• The majority of GLP-1 drug development firms are based in China (36%) and the US (28%)

  80% confidence

• The efficacy of GLP-1 medications in weight management presents opportunities for wider application in non-diabetic groups, combating the worldwide obesity crisis

  80% confidence

• Single-agonist segment currently holds the maximum share of the GLP-1 market

  80% confidence

• Parenteral route holds a larger share of the GLP-1 market and this trend is likely to remain the same in the coming decade

  80% confidence

• Lifestyle changes, influence of social media, celebrity endorsements and direct to consumer advertisements have led to a surge in the demand for GLP-1 drugs

  80% confidence

• Currently, small molecules category occupies the largest share of the GLP-1 market

  80% confidence

• Improvements in drug administration, including implantable devices, extended-release formulations, or non-invasive methods (like transdermal patches), may enhance patient satisfaction and broaden market appeal

  80% confidence

• Biologics segment is expected to capture the majority share (over 65%) of the GLP-1 market by 2035

  80% confidence

• Type 2 diabetes represents a larger market share but non-alcoholic steatohepatitis segment is anticipated to experience significant market expansion in the years ahead

  80% confidence

• Survodutide is likely to drive the GLP-1 market in the near future

  80% confidence

• Semaglutide holds the maximum share of the GLP-1 market at present

  80% confidence

• Long-acting GLP-1 agonists currently dominate the market and this trend is expected to persist due to longer duration of effect compared to short-acting agonists

  80% confidence

• Oral route of administration is likely to grow at a relatively higher CAGR

  80% confidence

• The short-acting GLP-1 agonist segment is expected to expand at a notably higher CAGR

  80% confidence

• The biologics sector is expected to expand at a comparatively higher CAGR due to distinct physiological characteristics such as stability, specificity, selectivity, and capacity to inhibit particular protein-protein interactions

  80% confidence

• Over the years, the market in Asia-Pacific is expected to grow at a higher CAGR

  80% confidence

• Tri-agonist segment is likely to grow at a relatively higher CAGR

  80% confidence

• North America accounts for the largest share of the GLP-1 market

  80% confidence

• More than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies

  80% confidence